Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
2.
J Clin Pharm Ther ; 45(1): 199-203, 2020 Feb.
Article in English | MEDLINE | ID: covidwho-838508

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Some patients with refractory depression who fail to respond to rapid injection of standard-dose ketamine are injected with high doses, but the safety and efficacy of this practice are unclear. CASE DESCRIPTION: A 57-year-old woman with refractory depression whose symptoms did not improve after 20-seconds intravenous injection of 0.5 mg/kg ketamine went into remission following eight, 1-minute intravenous injections of 1 mg/kg ketamine delivered over a 4-week period. By 6-month follow-up, no significant adverse events had occurred and cognitive function had improved. WHAT IS NEW AND CONCLUSION: High-dose intravenous injections of ketamine may stably improve depressive symptoms and cognitive function in patients with refractory depression who do not respond to rapid intravenous injection of standard-dose ketamine. The high-dose treatment appears to be associated with only mild side effects.


Subject(s)
Antidepressive Agents/administration & dosage , Depressive Disorder, Major/drug therapy , Depressive Disorder, Treatment-Resistant/drug therapy , Ketamine/administration & dosage , Antidepressive Agents/adverse effects , Coronavirus Infections/drug therapy , Depressive Disorder, Major/physiopathology , Depressive Disorder, Treatment-Resistant/physiopathology , Drug Synergism , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Injections, Intravenous , Ketamine/adverse effects , Middle Aged , Remission Induction , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL